Evidence map›Paper›PMID 26316911›Full record

ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada

Bone metastases affect prognosis but not effectiveness of third-line targeted therapies in patients with metastatic renal cell carcinoma.

Roberto Iacovelli, Daniele Santini, Mimma Rizzo, Alessandra Felici, Matteo Santoni, Elena Verzoni, Cristina Masini, Francesco Massari, Nicola Calvani, Alessandra Mosca and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Third-line treatment in metastatic renal cell carcinoma and bone metastases.Canadian Urological Association journal = Journal de l'Association des urologues du Canada
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 2 countries.

Roberto IacovelliDepartment of Radiology, Oncology and Human Pathology, Sapienza University of Rome, Rome, Italy;
Daniele SantiniDepartment of Radiology, Oncology and Human Pathology, Sapienza University of Rome, Rome, Italy;
Mimma RizzoDepartment of Radiology, Oncology and Human Pathology, Sapienza University of Rome, Rome, Italy;
Alessandra FeliciDepartment of Radiology, Oncology and Human Pathology, Sapienza University of Rome, Rome, Italy;
Matteo SantoniDepartment of Radiology, Oncology and Human Pathology, Sapienza University of Rome, Rome, Italy;
Elena VerzoniDepartment of Radiology, Oncology and Human Pathology, Sapienza University of Rome, Rome, Italy;
Cristina MasiniDepartment of Radiology, Oncology and Human Pathology, Sapienza University of Rome, Rome, Italy;
Francesco MassariDepartment of Radiology, Oncology and Human Pathology, Sapienza University of Rome, Rome, Italy;
Nicola CalvaniDepartment of Radiology, Oncology and Human Pathology, Sapienza University of Rome, Rome, Italy;
Alessandra MoscaDepartment of Radiology, Oncology and Human Pathology, Sapienza University of Rome, Rome, Italy;
Giuseppe ProcopioFondazione IRCCS Istituto Nazionale Tumori, Division of Medical Oncology, Rome, Italy.
Sapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTreatment of metastatic renal cell carcinoma (mRCC) has improved with the use of targeted therapies, but bone metastases continue to be negative prognostic factor.

methodsPatients with mRCC treated with everolimus (EV) or sorafenib (SO) after two previous lines of targeted therapies were included in the analysis. Overall survival (OS) and progression-free survival (PFS) were assessed based on the presence of bone metastases and type of therapy; they were also adjusted based on prognostic criteria.

resultsOf the 233 patients with mRCC, 76 had bone metastases. Of the 233 patients, EV and SO were administered in 143 and 90 patients, respectively. Median OS was 10.4 months in patients with BMs and 17.4 months in patients without bone metastases (p = 0.002). EV decreased the risk of death by 18% compared to SO (adjusted hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.74-0.91; p < 0.001), with comparable effects in patients with or without bone metastases. In the same manner, EV decreased the risk of progression by 12% compared to SO (adjusted HR 0.88, 95% CI 0.82-0.96; p = 0.002), but this difference was not significant in patients without bone metastases. The major limitations of the study are its retrospective nature, the heterogeneity of the methods to detect bone metastases, and the lack of data about patients treated with bisphosphonates.

conclusionsThe relative benefit of targeted therapies in mRCC is not affected by the presence of bone metastases, but patients without bone metastases have longer response to therapy and overall survival.

Identifiers

PMID26316911
PMCPMC4537338
OpenAlexW1906073601

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.